JP2018525367A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018525367A5 JP2018525367A5 JP2018504105A JP2018504105A JP2018525367A5 JP 2018525367 A5 JP2018525367 A5 JP 2018525367A5 JP 2018504105 A JP2018504105 A JP 2018504105A JP 2018504105 A JP2018504105 A JP 2018504105A JP 2018525367 A5 JP2018525367 A5 JP 2018525367A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- acid sequence
- pharmaceutical composition
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562198384P | 2015-07-29 | 2015-07-29 | |
| US62/198,384 | 2015-07-29 | ||
| US201662352637P | 2016-06-21 | 2016-06-21 | |
| US62/352,637 | 2016-06-21 | ||
| PCT/IB2016/054487 WO2017017623A1 (en) | 2015-07-29 | 2016-07-27 | Combined use of anti pd-1 and anti m-csf antibodies in the treatment of cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018525367A JP2018525367A (ja) | 2018-09-06 |
| JP2018525367A5 true JP2018525367A5 (https=) | 2019-09-05 |
| JP6840127B2 JP6840127B2 (ja) | 2021-03-10 |
Family
ID=56682136
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018504105A Expired - Fee Related JP6840127B2 (ja) | 2015-07-29 | 2016-07-27 | がんの治療における抗ｐｄ−１抗体および抗ｍ−ｃｓｆ抗体の併用 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US11001628B2 (https=) |
| EP (1) | EP3328425B1 (https=) |
| JP (1) | JP6840127B2 (https=) |
| KR (1) | KR20180034426A (https=) |
| CN (1) | CN108136003A (https=) |
| AU (1) | AU2016300208B2 (https=) |
| BR (1) | BR112018000212A2 (https=) |
| CA (1) | CA2991857A1 (https=) |
| CL (1) | CL2018000222A1 (https=) |
| IL (1) | IL256691A (https=) |
| JO (1) | JO3784B1 (https=) |
| MX (1) | MX2018001263A (https=) |
| PH (1) | PH12018500174A1 (https=) |
| RU (1) | RU2742494C2 (https=) |
| SA (1) | SA518390834B1 (https=) |
| TN (1) | TN2017000554A1 (https=) |
| TW (1) | TWI735456B (https=) |
| WO (1) | WO2017017623A1 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015048312A1 (en) | 2013-09-26 | 2015-04-02 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
| PE20170255A1 (es) | 2014-01-24 | 2017-03-22 | Dana Farber Cancer Inst Inc | Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas |
| HUE045065T2 (hu) | 2014-01-31 | 2019-12-30 | Novartis Ag | TIM-3 antitest molekulák és felhasználásaik |
| KR102442436B1 (ko) | 2014-03-14 | 2022-09-15 | 노파르티스 아게 | Lag-3에 대한 항체 분자 및 그의 용도 |
| KR20170060042A (ko) | 2014-09-13 | 2017-05-31 | 노파르티스 아게 | Alk 억제제의 조합 요법 |
| MX383464B (es) | 2015-07-13 | 2025-03-14 | Cytomx Therapeutics Inc | Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y métodos de uso de los mismos. |
| HRP20211058T8 (hr) | 2015-07-29 | 2021-11-26 | Novartis Ag | Kombinirane terapije koje sadrže molekule antitijela protiv lag-3 |
| IL300122A (en) | 2015-11-18 | 2023-03-01 | Merck Sharp ַ& Dohme Llc | Substances that bind to PD1 and/or LAG3 |
| AR112603A1 (es) * | 2017-07-10 | 2019-11-20 | Lilly Co Eli | Anticuerpos biespecíficos inhibidores de punto de control |
| US12398209B2 (en) | 2018-01-22 | 2025-08-26 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-PD-1 antibodies |
| US12174192B2 (en) | 2018-07-12 | 2024-12-24 | Corvus Pharmaceuticals, Inc. | Methods for detecting and treating cancers having adenosine pathway activation |
| US12116635B2 (en) | 2018-07-12 | 2024-10-15 | Corvus Pharmaceuticals, Inc. | Methods for detecting and treating cancers having adenosine pathway activation |
| WO2020044252A1 (en) * | 2018-08-31 | 2020-03-05 | Novartis Ag | Dosage regimes for anti-m-csf antibodies and uses thereof |
| MX2021009562A (es) * | 2019-02-12 | 2021-09-08 | Novartis Ag | Combinacion farmaceutica que comprende tno155 y un inhibidor de pd-1. |
| WO2020239558A1 (en) | 2019-05-24 | 2020-12-03 | Pfizer Inc. | Combination therapies using cdk inhibitors |
| EP3983440A1 (en) * | 2019-06-13 | 2022-04-20 | CytomX Therapeutics, Inc. | Use of an activatable anti-pdl1 antibody and an anti-ctla-4 antibody in a neoadjuvant combination therapy for the treatment of cancer |
| WO2020252349A1 (en) * | 2019-06-13 | 2020-12-17 | Cytomx Therapeutics, Inc. | Use of an activatable anti-pdl1 antibody and an anti-ctla-4 antibody in a combination therapy for the treatment of cancer |
| WO2021226984A1 (zh) | 2020-05-15 | 2021-11-18 | 三生国健药业（上海）股份有限公司 | 一种抗pd-1和pd-l1的四价双特异性抗体 |
| US20220168293A1 (en) | 2020-12-02 | 2022-06-02 | Pfizer Inc. | Time to resolution of axitinib-related adverse events |
| TW202327595A (zh) | 2021-10-05 | 2023-07-16 | 美商輝瑞大藥廠 | 用於治療癌症之氮雜內醯胺化合物的組合 |
| WO2023079428A1 (en) | 2021-11-03 | 2023-05-11 | Pfizer Inc. | Combination therapies using tlr7/8 agonist |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101899114A (zh) | 2002-12-23 | 2010-12-01 | 惠氏公司 | 抗pd-1抗体及其用途 |
| SI2311873T1 (sl) * | 2004-01-07 | 2018-12-31 | Novartis Vaccines And Diagnostics, Inc. | M-CSF-specifična monoklonska protitelesa in njihova uporaba |
| DK2439273T3 (da) | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
| RU2450018C2 (ru) * | 2006-08-23 | 2012-05-10 | Йеда Рисерч Энд Диверлопмент Ко. Лтд | Конъюгаты rgd-пептидов и фотосенсибилизаторов порфирина или (бактерио)хлорофилла и их применение |
| AU2007296259A1 (en) * | 2006-09-15 | 2008-03-20 | Janssen Pharmaceutica Nv | Combinations of class-I specific histone deacetylase inhibitors with proteasome inhibitors |
| CN101970499B (zh) | 2008-02-11 | 2014-12-31 | 治疗科技公司 | 用于肿瘤治疗的单克隆抗体 |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| JP2012500855A (ja) | 2008-08-25 | 2012-01-12 | アンプリミューン、インコーポレーテッド | Ｐｄ−１アンタゴニストおよび感染性疾患を処置するための方法 |
| AU2009288730B2 (en) | 2008-08-25 | 2013-06-20 | Amplimmune, Inc. | Compositions of PD-1 antagonists and methods of use |
| WO2011066342A2 (en) | 2009-11-24 | 2011-06-03 | Amplimmune, Inc. | Simultaneous inhibition of pd-l1/pd-l2 |
| AU2014309199B2 (en) * | 2013-08-20 | 2018-04-19 | Merck Sharp & Dohme Llc | Treating cancer with a combination of a PD-1 antagonist and dinaciclib |
| AR097306A1 (es) | 2013-08-20 | 2016-03-02 | Merck Sharp & Dohme | Modulación de la inmunidad tumoral |
| AR097584A1 (es) | 2013-09-12 | 2016-03-23 | Hoffmann La Roche | Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano |
| JP6595458B2 (ja) * | 2013-09-20 | 2019-10-23 | ブリストル−マイヤーズ スクイブ カンパニー | 腫瘍を処置するための抗ｌａｇ−３抗体と抗ｐｄ−１抗体との組合せ |
| PE20170255A1 (es) * | 2014-01-24 | 2017-03-22 | Dana Farber Cancer Inst Inc | Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas |
-
2016
- 2016-07-27 EP EP16750495.0A patent/EP3328425B1/en active Active
- 2016-07-27 KR KR1020187002247A patent/KR20180034426A/ko not_active Ceased
- 2016-07-27 AU AU2016300208A patent/AU2016300208B2/en not_active Ceased
- 2016-07-27 CN CN201680044470.5A patent/CN108136003A/zh active Pending
- 2016-07-27 RU RU2018106876A patent/RU2742494C2/ru active
- 2016-07-27 TN TNP/2017/000554A patent/TN2017000554A1/en unknown
- 2016-07-27 CA CA2991857A patent/CA2991857A1/en not_active Abandoned
- 2016-07-27 WO PCT/IB2016/054487 patent/WO2017017623A1/en not_active Ceased
- 2016-07-27 US US15/879,064 patent/US11001628B2/en not_active Expired - Fee Related
- 2016-07-27 MX MX2018001263A patent/MX2018001263A/es unknown
- 2016-07-27 BR BR112018000212A patent/BR112018000212A2/pt not_active IP Right Cessation
- 2016-07-27 JP JP2018504105A patent/JP6840127B2/ja not_active Expired - Fee Related
- 2016-07-28 JO JOP/2016/0162A patent/JO3784B1/ar active
- 2016-07-29 TW TW105124178A patent/TWI735456B/zh not_active IP Right Cessation
-
2018
- 2018-01-01 IL IL256691A patent/IL256691A/en unknown
- 2018-01-23 PH PH12018500174A patent/PH12018500174A1/en unknown
- 2018-01-26 CL CL2018000222A patent/CL2018000222A1/es unknown
- 2018-01-29 SA SA518390834A patent/SA518390834B1/ar unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018525367A5 (https=) | ||
| RU2018106876A (ru) | Новая комбинация для применения при лечении злокачественного новообразования | |
| IL288012B1 (en) | Antibody molecules against lag–3 and their use | |
| ZA202403388B (en) | Small molecules for treatement of cancer | |
| JP2019508013A5 (https=) | ||
| JP2018507220A5 (https=) | ||
| JP2016531150A5 (https=) | ||
| JP2018501197A5 (https=) | ||
| RU2018146886A (ru) | Пути терапевтического применения ингибитора c-raf | |
| FI3389699T3 (fi) | Kimeerisiä ja humanisoituja humaaneja monoklonaalisia ctla4-vasta-aineita ja niiden käyttötapoja | |
| JP2017529838A5 (https=) | ||
| PE20211767A1 (es) | Anticuerpos anti-hla-g, composiciones que comprenden anticuerpos anti-hla-g y metodos de uso de anticuerpos anti-hla-g | |
| RU2018105846A (ru) | Комбинация антагониста pd-1 с ингибитором egfr | |
| HRP20191034T1 (hr) | Pripravci koji sadrže anti-cd38 protutijela i lenalidomid | |
| RU2018123717A (ru) | Комбинированные лечения, их применения и способы | |
| PE20241623A1 (es) | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y usos de los mismos | |
| JP2011046732A5 (https=) | ||
| EA201890805A1 (ru) | Биспецифические антитела против cd3*cd19 | |
| RU2016130056A (ru) | Способы лечения кожной инфекции путем введения антагониста il-4r | |
| EA200801580A1 (ru) | Новые производные пирониндола и способ их получения | |
| RU2017120358A (ru) | Анти-il-1-бета антитела и способы их применения | |
| JP2017534645A5 (https=) | ||
| JP2017506669A5 (ja) | 膠芽腫の治療に使用するための組成物及びその使用 | |
| MX2019007404A (es) | Moleculas de union a adam9 y metodos de uso de las mismas. | |
| JP2018529661A5 (https=) |